Leticia De Mattos-Arruda

View all the researchers of IrsiCaixa

Leticia De Mattos-Arruda

Principal Investigator

Dr Leticia De Mattos-Arruda, MD, PhD is a physician-scientist medical oncologist who joined IrsiCaixa as principal investigator of the Neoantigens and Therapeutic Personalized Cancer Vaccines (NeoVaCan) group.

After she obtained her master’s and PhD degrees from the Autonomous University of Barcelona (UAB), she was employed at the Vall d’Hebron Institute of Oncology (Barcelona) from 2009 to 2014, conducting clinical trials and translational research projects. In 2010, she was awarded the European Society for Medical Oncology (ESMO) Translational Research Fellowship and, with a special grant from the Ontario Institute of Cancer Research, attended the 12the ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research. During this period she was recognized as follows: in 2012 and 2013, the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Merit Awards and, in 2014, the American Association for Cancer Research (AACR) Scholar-In-Training Award of the San Antonio Breast Cancer Symposium and the Advanced Programme in Oncology grant of the Spanish Cancer Association (AECC).

Following completion of her fellowship in Vall d’Hebron in 2014, she was a Visiting Scientist at the Memorial Sloan-Kettering Cancer Center (New York), working in Dr Reis-Filho’s laboratory. From 2015 to 2017, she was a Visiting Scientist at Cancer Research UK, where, in Dr Carlos Caldas’ laboratory at the Cambridge Institute, she investigated clonal and cellular heterogeneity in breast cancer metastatic sites and in the neoadjuvant breast cancer setting.

In 2017, she returned to Spain where she was appointed group leader/principal investigator at the Vall d'Hebron Institute of Oncology. She worked at the VHIO until May 2019 on characterizing the genomic and immune landscapes of metastatic breast cancer and studying intratumoral genetic heterogeneity with the goal of developing genomic and immune biomarkers for clinical applications. She also worked on identifying neoantigens with the aim of generating personalized immunotherapies for patients with cancer.

Dr De Mattos-Arruda is a member of ESMO, ASCO, AACR and the European Association for Cancer Research (EACR). From 2012 to 2018, she was an active member of the ESMO Young Oncologist Committee. From 2015 to 2017, she was president of the Alumni Club of the European Cancer Organisation (ECCO)-AACR-European Organisation for Research and Treatment of Cancer (EORTC)-ESMO Workshop on Methods in Clinical Cancer Research. She is also an advisory member of ECCO. In 2017, she was selected for the ESMO Leaders Generation Programme. She is also a faculty member for breast cancer  for ESMO, on the breast cancer 2018/2019 editorial board for ESMO Open: Cancer Horizons journal and is a member of the ESMO Translational Research and Precision Medicine Working Group working on the neoantigen prediction project. She has participated as an ad hoc expert member in the breast cancer advisory board of the European Medicines Agency (EMA).

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut


HR Excellence in Research

Member of:


In cooperation with: